Use of tumour markers in monitoring the course of ovarian cancer

Annals of Oncology

Volumn 10, Issue SUPPL. 1, 1999, Pages

  Rustin, Gordon J S ^a   Nelstrop, A E ^a   Bentzen, S M ^a   Piccart, M J ^b   Bertelsen, K ^c  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b JULES BORDET INSTITUTE   (Belgium)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

CA 125; Ovarian cancer; Progression; Relapse; Response; Tumour marker

Indexed keywords

CA 125 ANTIGEN; TUMOR MARKER;

CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DISEASE COURSE; ENDOMETRIOSIS; FOLLOW UP; HUMAN; MONITORING; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; RELAPSE;

EID: 0032962414     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0923-7534(20)31480-0     Document Type: Conference Paper

References (13)

1. Bast RC, Klug TL, John ES et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309: 883-7.
2. Tuxen MK, Soletormost G, Dombernowsky P. Tumour markers in the management of patients with ovarian cancer. Cancer Treat Rev 1995; 21: 215-45.
3. Rustin GJS, Nelstrop A, Stilwell J, Lambert HE for the North Thames Ovary Group. Savings obtained by CA 125 measurements during therapy for ovarian carcinoma. Eur J Cancer 1992; Vol 28 No 1: 79-82.
4. Rustin GJS, Nelstrop AE, McClean P et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996; Vol 14 No 5: 1545-51.
5. Rustin GJS, van der Burg MEL, Berek JS. Tumour Markers. Ann Oncol 1993; 4: S71-7.
6. Van der Burg MEL, Lammes FB, Verweij J. The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. Ann Oncol 1990; 1: 301-2.
7. Rustin GJS, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group study. Ann Oncol 1996; 7: 361-4.
8. Krebs HB, Goplerud DR, Kilpatrick SJ et al. The role of CA 125 as a tumour marker in ovarian carcinoma. Obstet Gynecol 1986; 67: 473-7.
9. Eisenhauer EA, ten Bokkel Huinink WM, Swenerton KD et al. European-Canadian randomised trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; Vol 12 No. 12: 2654-66.
10. Bridgewater JA, Nelstrop AE, Rustin JS et al. Comparison of clinical and CA 125 responses in patients treated with platinum or paclitaxel. Proc Am Soc Clin Oncol 1998; 358: 1382 (Abstr).
11. Rustin GJS, Nelstrop AE, Crawford M et al. Phase II trial of oral altretamine for relapsed ovarian carcinoma: Evaluation of defining response by serum CA 125. J Clin Oncol 1997; 15: 172-6.
12. Piccart MJ, Rustin GJS, Gore ME et al. Chapman & Hall Medical, Ovarian Cancer 4. Eds: Sharp F, Blackett T, Leake R, Berek J. 1996, Chapter 16: 153-63.
13. Rustin GJS, Quinnell TG, Johnson J et al. Trial of Isotretinoin and Calcitriol monitored by CA 125 in patients with ovarian cancer. Br J Cancer 1996; 74: 1479-81.